BRPI0921992A2 - moduladores tgr5 e métodos de uso destes - Google Patents

moduladores tgr5 e métodos de uso destes

Info

Publication number
BRPI0921992A2
BRPI0921992A2 BRPI0921992A BRPI0921992A BRPI0921992A2 BR PI0921992 A2 BRPI0921992 A2 BR PI0921992A2 BR PI0921992 A BRPI0921992 A BR PI0921992A BR PI0921992 A BRPI0921992 A BR PI0921992A BR PI0921992 A2 BRPI0921992 A2 BR PI0921992A2
Authority
BR
Brazil
Prior art keywords
methods
tgr5 modulators
tgr5
modulators
Prior art date
Application number
BRPI0921992A
Other languages
English (en)
Inventor
Pellicciari Roberto
Original Assignee
Intercept Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=41666760&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BRPI0921992(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Intercept Pharmaceuticals Inc filed Critical Intercept Pharmaceuticals Inc
Publication of BRPI0921992A2 publication Critical patent/BRPI0921992A2/pt
Publication of BRPI0921992B1 publication Critical patent/BRPI0921992B1/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J9/00—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of more than two carbon atoms, e.g. cholane, cholestane, coprostane
    • C07J9/005—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of more than two carbon atoms, e.g. cholane, cholestane, coprostane containing a carboxylic function directly attached or attached by a chain containing only carbon atoms to the cyclopenta[a]hydrophenanthrene skeleton
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Transplantation (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
BRPI0921992-7A 2008-11-19 2009-11-19 Compostos moduladores de tgr5, composição e seus usos BRPI0921992B1 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP08169460 2008-11-19
EP08169460.6 2008-11-19
PCT/US2009/065199 WO2010059859A1 (en) 2008-11-19 2009-11-19 Tgr5 modulators and methods of use thereof

Publications (2)

Publication Number Publication Date
BRPI0921992A2 true BRPI0921992A2 (pt) 2018-06-05
BRPI0921992B1 BRPI0921992B1 (pt) 2021-12-14

Family

ID=41666760

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0921992-7A BRPI0921992B1 (pt) 2008-11-19 2009-11-19 Compostos moduladores de tgr5, composição e seus usos

Country Status (10)

Country Link
US (1) US8999964B2 (pt)
EP (2) EP3150620B1 (pt)
JP (1) JP5639073B2 (pt)
CN (2) CN102282157B (pt)
AU (1) AU2009316484B2 (pt)
BR (1) BRPI0921992B1 (pt)
CA (1) CA2744135C (pt)
ES (2) ES2592452T3 (pt)
IL (1) IL212970A (pt)
WO (1) WO2010059859A1 (pt)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011140160A1 (en) 2010-05-06 2011-11-10 Bristol-Myers Squibb Company Bicyclic heteroaryl compounds as gpr119 modulators
TW201247627A (en) 2011-04-28 2012-12-01 Bristol Myers Squibb Co Novel bicyclic nitrogen containing heteroaryl TGR5 receptor modulators
HUE036887T2 (hu) * 2012-10-26 2018-08-28 Intercept Pharmaceuticals Inc Eljárás epesav-származékok elõállítására
SG11201503697TA (en) * 2012-11-28 2015-06-29 Intercept Pharmaceuticals Inc Treatment of pulmonary disease
WO2014200349A1 (en) 2013-06-13 2014-12-18 Fast Forward Pharmaceutical B.V. Cd40 signalling inhibitor and a further compound, wherein the further compound is a bile acid, a bile acid derivative, an tgr5-receptor agonist, an fxr agonist or a combination thereof, for the treatment of chronic inflammation, and the prevention of gastrointestinal cancer or fibrosis.
EP3626725B1 (en) * 2014-05-29 2022-11-30 Bar Pharmaceuticals S.r.l. Cholane derivatives for use in the treatment and/or prevention of fxr and tgr5/gpbar1 mediated diseases
EP3221331B1 (en) * 2014-11-19 2019-09-18 Nzp Uk Limited 6-alkyl-7-hydroxy-4-en-3-one steroids as intermediates for the production of steroidal fxr modulators
EA033445B1 (ru) * 2014-11-19 2019-10-31 Nzp Uk Ltd 5-бета-6-алкил-7-гидрокси-3-оновые стероиды в качестве промежуточных соединений для получения стероидных модуляторов fxr
JP6698085B2 (ja) * 2014-11-19 2020-05-27 エヌゼットピー ユーケー リミテッド ステロイドＦＸＲモジュレーター製造のための中間体としての６α−アルキル−６，７−ジオン−ステロイド
EP3221333B1 (en) * 2014-11-19 2019-07-24 NZP UK Limited 6.alpha.-alkyl-3,7-dione steroids as intermediates for the production of steroidal fxr modulators
HK1244708A1 (zh) * 2014-11-26 2018-08-17 英安塔制药有限公司 作爲fxr/tgr5激动剂的胆汁酸类似物及其使用方法
CN105348365A (zh) * 2014-12-03 2016-02-24 四川百利药业有限责任公司 一种胆酸衍生物及其制备方法、药物组合物和用途
CN104523703A (zh) * 2014-12-24 2015-04-22 聂飚 一种游离脂肪酸转运蛋白小分子抑制物的应用
CN104672290B (zh) * 2015-01-05 2017-06-06 北京普禄德医药科技有限公司 一种用于预防或治疗fxr‑介导的疾病的药物及其制备方法和用途
CN105330554B (zh) 2015-02-15 2017-07-11 上海迪赛诺药业股份有限公司 手性环丙基乙炔基叔醇类化合物的合成方法
CN105985396A (zh) 2015-02-16 2016-10-05 苏州泽璟生物制药有限公司 氘代鹅去氧胆酸衍生物以及包含该化合物的药物组合物
US10800807B2 (en) 2015-06-19 2020-10-13 Intercept Pharmaceuticals, Inc. TGR5 modulators and methods of use thereof
CN106854229A (zh) * 2015-12-08 2017-06-16 陈剑 一类脂肪酸盐,其制备及其在医药上的应用
GB201608776D0 (en) 2016-05-18 2016-06-29 Dextra Lab Ltd Methods and compounds
GB201608777D0 (en) 2016-05-18 2016-06-29 Dextra Lab Ltd Compounds
WO2018054300A1 (zh) * 2016-09-20 2018-03-29 江苏豪森药业集团有限公司 胆酸衍生物游离碱，晶型及其制备方法和应用
GB201812382D0 (en) 2018-07-30 2018-09-12 Nzp Uk Ltd Compounds
BR112022006546A2 (pt) 2019-10-07 2022-08-30 Kallyope Inc Agonistas de gpr119
CA3173731A1 (en) 2020-02-28 2021-09-02 Kallyope, Inc. Gpr40 agonists
CN116323608A (zh) 2020-05-19 2023-06-23 卡尔优普公司 Ampk活化剂
EP4172162A4 (en) 2020-06-26 2024-08-07 Kallyope, Inc. AMPK ACTIVATORS

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2696934B1 (fr) * 1992-10-20 1995-06-02 Conservatoire Nal Arts Metiers Dérivés de stéroïdes naturels 3B hydroxyles ayant des propriétés de déclenchement et de stimulation de l'immunité, composition les contenant et procédé pour les obtenir.
CA2514547A1 (en) 2003-01-28 2004-08-12 Takeda Pharmaceutical Company Limited Receptor agonists
JP5292310B2 (ja) * 2007-01-19 2013-09-18 インターセプト ファーマシューティカルズ， インコーポレイテッド Ｔｇｒ５調節剤としての２３−置換胆汁酸およびその使用方法

Also Published As

Publication number Publication date
JP2012509349A (ja) 2012-04-19
EP3150620A1 (en) 2017-04-05
IL212970A0 (en) 2011-07-31
EP2373673B1 (en) 2016-07-27
AU2009316484B2 (en) 2015-04-16
IL212970A (en) 2017-07-31
ES2774368T3 (es) 2020-07-20
CN102282157A (zh) 2011-12-14
BRPI0921992B1 (pt) 2021-12-14
CN102282157B (zh) 2017-02-22
CN106380502A (zh) 2017-02-08
EP2373673A1 (en) 2011-10-12
ES2592452T3 (es) 2016-11-30
US8999964B2 (en) 2015-04-07
JP5639073B2 (ja) 2014-12-10
CA2744135C (en) 2017-07-04
WO2010059859A1 (en) 2010-05-27
AU2009316484A1 (en) 2010-05-27
EP3150620B1 (en) 2020-01-08
US20110263555A1 (en) 2011-10-27
CA2744135A1 (en) 2010-05-27

Similar Documents

Publication Publication Date Title
BRPI0916735A2 (pt) moduladores de tgr5 e métodos de uso do mesmo
BRPI0808684A2 (pt) moduladores de tgr5 e métodos de uso destes
BRPI0921983A2 (pt) moduladores tgr5 e métodos de uso dos mesmos
BRPI0922708A2 (pt) peptídeos mini-hepcidina e métodos de uso do mesmo
EP2301812A4 (en) PARKING AID DEVICE AND PARKING AID METHOD
EP2326631A4 (en) MIF MODULATORS
BRPI0915717A2 (pt) ferramenta de avaliação de cascalho e métodos de uso
BR112013014321A2 (pt) moduladores inovadores e métodos de uso
BRPI0918449A2 (pt) compostos de anel espiro-tricíclico como moduladores de beta-secretas e métodos de uso
EP2259678A4 (en) PROTEIN KINASE MODULATORS
BR112012018329A2 (pt) agentes de coloração e métodos de uso destes
BRPI1014544A2 (pt) anticorpors anti-il-17f e metodos de uso dos mesmos
BRPI0906186A2 (pt) composto e uso de um composto
DK2349430T3 (da) KATETERISERINGANORDNING og -kit
PT2376533T (pt) Formulação de anticorpos
EP2329156A4 (en) Temporary fasteners
BRPI0916769A2 (pt) derivados de benzilbenzeno deuterados e métodos de uso
BRPI0907231A2 (pt) pirrolpirimidinas e pirrolpiridinas
PL2349143T5 (pl) Instrument wprowadzający
ES2409933T8 (es) Dispositivo de instalación de parabrisas y método de uso
ECSP10010558A (es) Tiazolopiridin-2-iloxi-fenil y tiazolopirazin-2-iloxi-fenil aminas como moduladores de la leucotrieno a4 hidrolasa
DK2325662T3 (da) Multi-indlæsnings- og multi-udlæsningsanalysator
BRPI0922295A2 (pt) mistura aceleradora e método de uso
EP2109633A4 (en) POLYBENZIMIDAZOLE POLYETHERKETONE KETONE MIXTURES AND MIXABLE MIXTURES
BRPI0908893A2 (pt) Modulação enzimática e de receptores

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]

Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS.

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B25G Requested change of headquarter approved

Owner name: INTERCEPT PHARMACEUTICALS, INC. (US)

B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 19/11/2009, OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF, QUE DETERMINA A ALTERACAO DO PRAZO DE CONCESSAO.

B21F Lapse acc. art. 78, item iv - on non-payment of the annual fees in time

Free format text: REFERENTE A 14A ANUIDADE.

B24J Lapse because of non-payment of annual fees (definitively: art 78 iv lpi, resolution 113/2013 art. 12)

Free format text: EM VIRTUDE DA EXTINCAO PUBLICADA NA RPI 2749 DE 12-09-2023 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDA A EXTINCAO DA PATENTE E SEUS CERTIFICADOS, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.